secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2024-05-08T23:59:59+00:00
Accession:  0001193125-24-134284
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX reports positive Phase 1a data for CX-904: no CRS, 33% response rate in pancreatic cancer
--------------------------------------------------------------------------------

- CX-904 demonstrated favorable safety: no CRS of any grade in step-dosing; no Grade >1 CRS overall.
- In 6 efficacy-evaluable pancreatic cancer patients, 2 confirmed partial responses (33%) and all 6 had disease control.
- One patient achieved 83% tumor reduction at 6 mg; another 51% at 5 mg; both remained on treatment.
- Preliminary PK/PD data support PROBODY T-cell engager mechanism: maintained masking and CD8+ T-cell margination.
- Dose escalation continues; Phase 1b expansion in EGFR-positive tumors planned with partner Amgen.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000119312524134284/0001193125-24-134284-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000119312524134284/d835346d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-134284

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer